{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:04:58Z","timestamp":1789473898307,"version":"build-2803163510"},"reference-count":37,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Corbus Pharmaceuticals Inc."},{"name":"CSPC Megalith Biopharmaceutical Co., Ltd."}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The adhesion protein nectin-4 is a clinically validated tumor-selective antigen that is overexpressed across multiple cancer types and has been successfully exploited as a target for antibody\u2013drug conjugates (ADCs), most notably enfortumab vedotin (EV), which is approved for the treatment of urothelial carcinoma. In this study, we report the design and preclinical characterization of a second-generation nectin-4\u2013targeted ADC, CRB-701 (also identified as SYS6002). CRB-701 was synthesized using microbial transglutaminase technology to conjugate two molecules of monomethyl auristatin E (MMAE) via a cleavable linker to a highly selective, high-affinity anti\u2013nectin-4 monoclonal antibody. CRB-701 exhibited potent in vitro cytotoxicity in nectin-4\u2013expressing cell lines and in vivo antitumor activity in cell line-derived and patient-derived murine xenograft models of human cancer (cell line-derived models: PC-3-NECTIN4 prostate cancer, MDA-MB-468 breast cancer, and HT1376 bladder cancer; patient-derived model: BL0597 bladder cancer), exhibiting efficacy similar to or greater than EV across tumors with varying levels of nectin-4 expression. CRB-701 delivered high levels of MMAE upon internalization in tumor cells and was markedly more stable in circulation than EV, with lower systemic MMAE release, an approximately twofold longer half-life, and at least a twofold higher safety margin in monkeys. These results suggest that CRB-701 may be a promising alternative therapeutic for the treatment of nectin-4\u2013expressing tumors, providing a more favorable therapeutic window and potentially enabling regimens with higher doses and less frequent dosing than those required for EV, the only currently approved nectin-4\u2013targeting ADC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>CRB-701 is a nectin-4\u2013targeted ADC. CRB-701 showed similar or superior antitumor activity, better stability in plasma, and was associated with lower systemic MMAE release than EV, the only approved nectin-4\u2013targeted ADC. CRB-701 offers a promising alternative for treatment of nectin-4\u2013expressing tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0799","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:52:31Z","timestamp":1787586751000},"page":"2164-2176","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRB-701: A Second-generation Nectin-4\u2013Targeted Antibody\u2013Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1972-8567","authenticated-orcid":false,"given":"Zhaopeng","family":"Sun","sequence":"first","affiliation":[{"name":"1CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-5345","authenticated-orcid":false,"given":"Mo","family":"Dan","sequence":"additional","affiliation":[{"name":"1CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1560-8008","authenticated-orcid":false,"given":"Lu","family":"Lv","sequence":"additional","affiliation":[{"name":"1CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8760-2079","authenticated-orcid":false,"given":"Mingyue","family":"Shen","sequence":"additional","affiliation":[{"name":"1CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6588-9573","authenticated-orcid":false,"given":"Can","family":"Yuan","sequence":"additional","affiliation":[{"name":"1CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6189-7079","authenticated-orcid":false,"given":"Congcong","family":"Niu","sequence":"additional","affiliation":[{"name":"1CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6556-3053","authenticated-orcid":false,"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"1CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0868-4812","authenticated-orcid":false,"given":"Xixin","family":"Hu","sequence":"additional","affiliation":[{"name":"1CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8913-2194","authenticated-orcid":false,"given":"Xiwu","family":"Hui","sequence":"additional","affiliation":[{"name":"1CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5928-4572","authenticated-orcid":false,"given":"Andrew","family":"Kolodziej","sequence":"additional","affiliation":[{"name":"2Corbus Pharmaceuticals Inc., Norwood, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"2026091507301864500_bib1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"2026091507301864500_bib2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026091507301864500_bib3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"2026091507301864500_bib4","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.7150\/thno.51299","article-title":"A general Fc engineering platform for the next generation of antibody therapeutics","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"2026091507301864500_bib5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/abt\/tbaf004","article-title":"Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors","volume":"8","author":"Cheng","year":"2025","journal-title":"Antib Ther"},{"key":"2026091507301864500_bib6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"2026091507301864500_bib7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026091507301864500_bib8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1158\/1535-7163.MCT-24-0983","article-title":"Broadening the therapeutic window of ADCs using site-specific bioconjugation showcased by an MMAE-containing peptide linker in a CD79b-targeting ADC","volume":"24","author":"Probst","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"2026091507301864500_bib9","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026091507301864500_bib10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/annonc\/mdw678","article-title":"Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer","volume":"28","author":"M-Rabet","year":"2017","journal-title":"Ann Oncol"},{"key":"2026091507301864500_bib11","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.1158\/0008-5472.Can-09-0016","article-title":"Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res"},{"key":"2026091507301864500_bib12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13046-015-0144-7","article-title":"Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer","volume":"34","author":"Nishiwada","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"2026091507301864500_bib13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1309\/ajcpgxk0fr4mhihb","article-title":"Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker","volume":"134","author":"DeRycke","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"2026091507301864500_bib14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.18632\/oncotarget.28299","article-title":"Nectin-4 is widely expressed in head and neck squamous cell carcinoma","volume":"13","author":"Sanders","year":"2022","journal-title":"Oncotarget"},{"key":"2026091507301864500_bib15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-019-0824-z","article-title":"Over-expression of nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients","volume":"19","author":"Deng","year":"2019","journal-title":"Cancer Cell Int"},{"key":"2026091507301864500_bib16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3892\/ijo.2021.5273","article-title":"Role of nectin-4 protein in cancer (Review)","volume":"59","author":"Liu","year":"2021","journal-title":"Int J Oncol"},{"key":"2026091507301864500_bib17","volume-title":"PADCEV (enfortumab vedotin-ejfv) for injection, for intravenous use: US prescribing information","author":"Astellas Pharma US, Inc","year":"2023"},{"key":"2026091507301864500_bib18","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/nbt.2968","article-title":"Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates","volume":"32","author":"Lyon","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2026091507301864500_bib19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/cpt.3383","article-title":"Population pharmacokinetic modeling and exposure\u2013response analysis for the antibody\u2013drug conjugate enfortumab vedotin in locally advanced or metastatic urothelial carcinoma","volume":"116","author":"Zuo","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2026091507301864500_bib20","doi-asserted-by":"publisher","first-page":"113615","DOI":"10.1016\/j.ab.2020.113615","article-title":"Recent progress in transglutaminase-mediated assembly of antibody-drug conjugates","volume":"595","author":"Schneider","year":"2020","journal-title":"Anal Biochem"},{"key":"2026091507301864500_bib21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"key":"2026091507301864500_bib22","doi-asserted-by":"publisher","first-page":"e18572","DOI":"10.1111\/jcmm.18572","article-title":"Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer","volume":"28","author":"Weiten","year":"2024","journal-title":"J Cell Mol Med"},{"key":"2026091507301864500_bib23","doi-asserted-by":"publisher","first-page":"115534","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026091507301864500_bib24","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1535-7163.Mct-21-0875","article-title":"BT8009; a nectin-4 targeting bicycle toxin conjugate for treatment of solid tumors","volume":"21","author":"Rigby","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"12_Supplement","key":"2026091507301864500_bib25","doi-asserted-by":"publisher","first-page":"C121","DOI":"10.1158\/1535-7163.Targ-23-c121","article-title":"Abstract C121: development of CRB-701 (SYS6002): a novel site-specific, nectin-4 targeting ADC","volume":"22","author":"Brake","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026091507301864500_bib26","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody\u2013drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"2026091507301864500_bib27","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/1535-7163.Mct-22-0743","article-title":"Preclinical evaluation of 9MW2821, a site-specific monomethyl auristatin E-based antibody-drug conjugate for treatment of nectin-4-expressing cancers","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026091507301864500_bib28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/abt\/tbaf010","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antibody Ther"},{"key":"2026091507301864500_bib29","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1021\/bc500357n","article-title":"Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy","volume":"25","author":"Tumey","year":"2014","journal-title":"Bioconjug Chem"},{"key":"2026091507301864500_bib30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11274-020-02829-y","article-title":"A recent update on the use of microbial transglutaminase for the generation of biotherapeutics","volume":"36","author":"Doti","year":"2020","journal-title":"World J Microbiol Biotechnol"},{"key":"2026091507301864500_bib31","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091507301864500_bib32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2026091507301864500_bib33","volume-title":"Padcev: EPAR \u2013 public assessment report. EMA\/249357\/2022","author":"European Medicines Agency","year":"2022"},{"key":"2026091507301864500_bib34","article-title":"Padcev, INN-enfortumab vedotin: EMA summary of product characteristics","author":"European Medicines Agency","year":"2023"},{"issue":"5_suppl","key":"2026091507301864500_bib35","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1200\/jco.2025.43.5_suppl.807","article-title":"Phase I dose-escalation study of the next-generation nectin-4 targeting antibody\u2013drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid tumors","volume":"43","author":"Perez","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 2","key":"2026091507301864500_bib36","doi-asserted-by":"publisher","first-page":"S593","DOI":"10.1016\/j.annonc.2025.08.1536","article-title":"Phase I\/II study of the next-generation Nectin-4-targeting antibody\u2013drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours","volume":"36","author":"Perez","year":"2025","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"2026091507301864500_bib37","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/jco.2024.42.16_suppl.3151","article-title":"Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate","volume":"42","author":"Ye","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0799\/3824047\/crc-25-0799.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2164\/3829832\/crc-25-0799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2164\/3829832\/crc-25-0799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:30:24Z","timestamp":1789471824000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/9\/2164\/788050\/CRB-701-A-Second-generation-Nectin-4-Targeted"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0799","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33790136","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790148","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790217","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790205","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790190","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790160","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790172","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790184","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790130","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790196","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790142","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790154","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790166","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790211","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790178","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790157","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790202","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790169","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790214","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790139","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790208","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790181","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790193","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790151","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790163","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790175","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790187","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790199","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790133","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33790145","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8715944","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}